Mechanistically, MEK inhibition raises BIM levels, whereas panobinostat dissociates BIM/MCL-1 and BIM/BCL-xL complexes in MM cells by acting as a MCL-1 and BCL-xL inhibitor. Here, BCL2L11 is linked to Miyoshi myopathy.